X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (252) 252
Publication (33) 33
Patent (12) 12
Newspaper Article (4) 4
Book / eBook (1) 1
Book Review (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (92) 92
index medicus (71) 71
female (55) 55
hematology (49) 49
male (48) 48
aged (44) 44
middle aged (44) 44
adult (41) 41
chronic myeloid leukemia (37) 37
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (34) 34
oncology (33) 33
chronic myelogenous leukemia (28) 28
cancer (24) 24
imatinib (24) 24
aged, 80 and over (23) 23
imatinib mesylate (23) 23
dasatinib (21) 21
life sciences (19) 19
chronic myeloid-leukemia (18) 18
pyrimidines - adverse effects (18) 18
therapy (18) 18
treatment outcome (18) 18
analysis (17) 17
leukemia (17) 17
nilotinib (17) 17
pyrimidines - administration & dosage (17) 17
immunology (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - genetics (16) 16
microbiology (16) 16
protein kinase inhibitors - adverse effects (16) 16
protein kinase inhibitors - therapeutic use (16) 16
benzamides (15) 15
follow-up (15) 15
fusion proteins, bcr-abl - genetics (15) 15
tyrosine (15) 15
abridged index medicus (14) 14
antineoplastic agents (14) 14
dendritic cells - immunology (14) 14
antineoplastic agents - adverse effects (13) 13
antineoplastic agents - therapeutic use (13) 13
survival (13) 13
tyrosine kinase inhibitor (13) 13
tyrosine kinase inhibitors (13) 13
beer (12) 12
biochemistry (12) 12
chemistry (12) 12
cml patients (12) 12
compositions thereof (12) 12
culture media (12) 12
enzymology (12) 12
human necessities (12) 12
hygiene (12) 12
medical or veterinary science (12) 12
metallurgy (12) 12
microorganisms or enzymes (12) 12
mutation or genetic engineering (12) 12
piperazines - administration & dosage (12) 12
preparations for medical, dental, or toilet purposes (12) 12
propagating, preserving or maintaining microorganisms (12) 12
prospective studies (12) 12
pyrimidines - therapeutic use (12) 12
specific therapeutic activity of chemical compounds ormedicinal preparations (12) 12
spirits (12) 12
surgery (12) 12
vinegar (12) 12
wine (12) 12
antimitotic agents (11) 11
antineoplastic agents - administration & dosage (11) 11
article (11) 11
cml (11) 11
leukemia, myelogenous, chronic, bcr-abl positive - pathology (11) 11
medicine & public health (11) 11
dendritic cells (10) 10
disease-free survival (10) 10
follow-up studies (10) 10
hemic and lymphatic diseases (10) 10
patients (10) 10
protein kinase inhibitors - administration & dosage (10) 10
recurrence (10) 10
research (10) 10
risk factors (10) 10
young adult (10) 10
adolescent (9) 9
chemotherapy (9) 9
fusion proteins, bcr-abl - antagonists & inhibitors (9) 9
genetic aspects (9) 9
hematology, oncology and palliative medicine (9) 9
human health and pathology (9) 9
leukemia, myeloid, chronic-phase - drug therapy (9) 9
myeloid leukemia (9) 9
protein-tyrosine kinase (9) 9
survival rate (9) 9
time factors (9) 9
animals (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
expression (8) 8
france (8) 8
gene expression (8) 8
mice (8) 8
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (254) 254
French (13) 13
German (4) 4
Portuguese (2) 2
Spanish (2) 2
Danish (1) 1
Greek (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Despite outstanding progress achieved from the development of 3 generations of ATP-competitive TKIs with increasing BCR-ABL inhibitory potency, some... 
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S29 - S29
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2018, Volume 18, pp. S23 - S24
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Science, ISSN 0036-8075, 3/2013, Volume 339, Issue 6126, pp. 1448 - 1453
Type I interferons (IFN-α and IFN-β) are important for protection against many viral infections, whereas type II interferon (IFN-γ) is essential for host... 
Monocytes | Messenger RNA | Tuberculosis | Mycobacterium tuberculosis | Antimicrobials | REPORTS | Leprosy | Infections | Skin | Lesions | Gene expression | LISTERIA-MONOCYTOGENES | ACTIVATION | PROFILES | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | HUMAN TUBERCULOSIS | IL-1-BETA | INDUCTION | DEPENDENT ANTIMICROBIAL PATHWAY | SARCOIDOSIS | LEPROSY | Up-Regulation | Interferon-beta - immunology | Humans | Transcriptome | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase - genetics | Monocytes - metabolism | Monocytes - immunology | Interferon-gamma - metabolism | Antimicrobial Cationic Peptides - metabolism | RNA, Messenger - metabolism | Receptors, Calcitriol - genetics | Mycobacterium leprae - immunology | Interferon-beta - genetics | Interleukin-10 - metabolism | beta-Defensins - metabolism | Interferon-gamma - genetics | Antimicrobial Cationic Peptides - genetics | Leprosy, Lepromatous - genetics | Mycobacterium leprae - physiology | Leprosy, Tuberculoid - immunology | beta-Defensins - genetics | Leprosy, Lepromatous - immunology | RNA, Messenger - genetics | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase - metabolism | Microbial Viability | Receptors, Calcitriol - metabolism | Leprosy, Tuberculoid - genetics | Tuberculosis - immunology | Leprosy, Lepromatous - metabolism | Interferon-beta - metabolism | Tuberculosis - genetics | Leprosy, Tuberculoid - metabolism | Interferon-gamma - immunology | Interleukin-10 - genetics | Interleukins | Physiological aspects | Host-parasite relationships | Anti-infective agents | Interferon | Genetic aspects | Health aspects | Antimicrobial agents | Pathogenesis | Genes | Bacteria | Human behavior | Antiinfectives and antibacterials | Digital signatures
Journal Article
International Journal of Hematology, ISSN 0925-5710, 10/2018, Volume 108, Issue 4, pp. 355 - 364
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 10/2018, Volume 25, Issue 11, pp. 3271 - 3279
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 12/2016, Volume 23, Issue S5, pp. 737 - 745
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2018, Volume 180, Issue 1, pp. 24 - 32
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 10/2007, Volume 176, Issue 8, pp. 814 - 818
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2019, Volume 94, Issue 3, pp. 346 - 357
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients... 
CHRONIC MYELOGENOUS LEUKEMIA | MAJOR MOLECULAR RESPONSE | PHASE | THERAPY | IMATINIB DISCONTINUATION | DASATINIB | HEMATOLOGY | INTERIM ANALYSIS | CML PATIENTS | CHRONIC MYELOID-LEUKEMIA | FRONTLINE NILOTINIB | Tyrosine | Chronic diseases | Phenols | Leukemia | Critical Review
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article